Nuklearmedizin 2019; 58(02): 166
DOI: 10.1055/s-0039-1683655
Poster
PET und SPECT: Onkologie
Georg Thieme Verlag KG Stuttgart · New York

Volumetric Ga-68-DOTA-TATE PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Neuroendocrine Tumors

F Ohlendorf
1   Medizinische Hochschule Hannover, Klinik für Nuklearmedizin, Hannover
,
JM Sohns
1   Medizinische Hochschule Hannover, Klinik für Nuklearmedizin, Hannover
,
T Brunkhorst
1   Medizinische Hochschule Hannover, Klinik für Nuklearmedizin, Hannover
,
TL Ross
1   Medizinische Hochschule Hannover, Klinik für Nuklearmedizin, Hannover
,
FM Bengel
1   Medizinische Hochschule Hannover, Klinik für Nuklearmedizin, Hannover
,
T Derlin
1   Medizinische Hochschule Hannover, Klinik für Nuklearmedizin, Hannover
› Author Affiliations
Further Information

Publication History

Publication Date:
27 March 2019 (online)

Also available at
 
 

    Ziel/Aim:

    A quantitative imaging biomarker is desirable to provide a comprehensive measure of whole-body tumor burden in patients with metastatic neuroendocrine tumors, and to standardize the evaluation of treatment-related changes. Therefore, we evaluated volumetric parameters for quantification of whole-body tumor burden from somatostatin receptor (SSTR)-targeted PET/CT.

    Methodik/Methods:

    33 patients with metastastic G1/G2 gastroenteropancreatic tumors who underwent a Ga-68-DOTA-TATE PET/CT for staging of disease before initiation of peptide receptor radionuclide therapy were included in this retrospective analysis. Volumetric parameters of tumor lesions, that is, SSTR-derived tumor volume (SSTR-TV) and total lesion SSTR (TL-SSTR), were calculated for each patient using a 3-dimensional segmentation and computerized volumetric technique with a 40% SUVmax cut-off, and compared with serum chromogranin A (CgA) levels, and progression-free survival. In a subgroup of 13 patients, volumetric parameters were applied for treatment monitoring.

    Ergebnisse/Results:

    Median baseline SSTR-TV was 96 cm3 (IQR, 41 – 321), whereas TL-SSTR was 1237 cm3 (IQR, 572 – 6930 cm3). There was a mild, but statistically significant correlation between baseline CgA levels and whole-body SSTR-TV and whole-body TL-SSTR (rs= 0.55; P = 0.001 and rs= 0.48, P = 0.004, respectively). There was a trend towards shorter PFS in patients with high SSTR-TV (≥100 cm3, Hazard Ratio 1.34 (95% CI 0.67 – 2.87), P = 0.40), and high TL-SSTR (≥1237 cm3, Hazard Ratio 1.57 (95% CI 0.81 – 3.41), P = 0.19). Using PET/CT as gold standard for treatment monitoring (PERCIST 1.0), changes in CgA provided discordant results in 8/13 cases, whereas SSTR-TV was discordant in 7/13 cases, and TL-SSTR in 6/13 cases.

    Schlussfolgerungen/Conclusions:

    SSTR-derived volumetric parameters provide a quantitative imaging biomarker for whole-body tumor burden. The value for assessment of treatment response requires further investigation.


    #